Concepts (337)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hearing Loss | 64 | 2025 | 199 | 14.020 |
Why?
|
| Hearing Aids | 12 | 2025 | 31 | 3.810 |
Why?
|
| Cognitive Dysfunction | 12 | 2024 | 283 | 2.430 |
Why?
|
| Cochlear Implants | 4 | 2017 | 56 | 1.490 |
Why?
|
| Aged | 66 | 2025 | 19994 | 1.330 |
Why?
|
| Ependymoma | 3 | 2025 | 139 | 1.260 |
Why?
|
| Geriatrics | 3 | 2021 | 62 | 1.260 |
Why?
|
| Atherosclerosis | 9 | 2025 | 926 | 1.210 |
Why?
|
| Loneliness | 3 | 2025 | 32 | 0.940 |
Why?
|
| Aging | 15 | 2024 | 1187 | 0.940 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2024 | 191 | 0.930 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 664 | 0.920 |
Why?
|
| Brain Neoplasms | 6 | 2023 | 1223 | 0.900 |
Why?
|
| Community Health Workers | 2 | 2022 | 73 | 0.850 |
Why?
|
| Gangliosides | 1 | 2024 | 67 | 0.830 |
Why?
|
| Male | 72 | 2025 | 62073 | 0.820 |
Why?
|
| Mobility Limitation | 2 | 2021 | 32 | 0.810 |
Why?
|
| Aged, 80 and over | 31 | 2025 | 6550 | 0.800 |
Why?
|
| Retinoblastoma | 2 | 2021 | 79 | 0.790 |
Why?
|
| Retinal Neoplasms | 2 | 2021 | 68 | 0.790 |
Why?
|
| Activities of Daily Living | 3 | 2022 | 403 | 0.780 |
Why?
|
| Quality of Life | 6 | 2024 | 2023 | 0.770 |
Why?
|
| Female | 72 | 2025 | 67899 | 0.750 |
Why?
|
| Accidental Falls | 3 | 2025 | 114 | 0.750 |
Why?
|
| Depression | 5 | 2023 | 1292 | 0.730 |
Why?
|
| Humans | 98 | 2025 | 126057 | 0.710 |
Why?
|
| Dementia | 6 | 2022 | 413 | 0.710 |
Why?
|
| Health Services for the Aged | 1 | 2021 | 34 | 0.690 |
Why?
|
| Pyrimidines | 2 | 2021 | 403 | 0.680 |
Why?
|
| Geriatric Assessment | 5 | 2024 | 182 | 0.660 |
Why?
|
| Cognition | 8 | 2024 | 783 | 0.630 |
Why?
|
| Exercise | 3 | 2024 | 837 | 0.620 |
Why?
|
| Hearing | 7 | 2023 | 61 | 0.600 |
Why?
|
| Deaf-Blind Disorders | 1 | 2018 | 1 | 0.590 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2018 | 3 | 0.590 |
Why?
|
| Pyrazoles | 1 | 2021 | 327 | 0.580 |
Why?
|
| Neurosurgical Procedures | 2 | 2024 | 297 | 0.570 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2020 | 481 | 0.570 |
Why?
|
| Speech Perception | 3 | 2024 | 52 | 0.540 |
Why?
|
| Congresses as Topic | 1 | 2018 | 173 | 0.530 |
Why?
|
| Communication | 2 | 2022 | 513 | 0.530 |
Why?
|
| Body Composition | 1 | 2020 | 541 | 0.520 |
Why?
|
| Mental Health Services | 1 | 2020 | 259 | 0.520 |
Why?
|
| Cross-Sectional Studies | 16 | 2024 | 3649 | 0.510 |
Why?
|
| Prospective Studies | 16 | 2025 | 6090 | 0.510 |
Why?
|
| Audiometry, Pure-Tone | 9 | 2025 | 23 | 0.490 |
Why?
|
| Health Education | 4 | 2025 | 223 | 0.480 |
Why?
|
| Independent Living | 4 | 2023 | 62 | 0.470 |
Why?
|
| Cost of Illness | 1 | 2017 | 283 | 0.460 |
Why?
|
| Stress, Psychological | 1 | 2020 | 547 | 0.460 |
Why?
|
| Health Care Costs | 1 | 2019 | 383 | 0.460 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 151 | 0.460 |
Why?
|
| Middle Aged | 23 | 2025 | 27321 | 0.460 |
Why?
|
| Germ-Line Mutation | 4 | 2025 | 351 | 0.450 |
Why?
|
| Vision Disorders | 5 | 2023 | 188 | 0.450 |
Why?
|
| Computers | 1 | 2014 | 69 | 0.440 |
Why?
|
| Ear Diseases | 1 | 2014 | 21 | 0.440 |
Why?
|
| Societies, Medical | 1 | 2018 | 725 | 0.430 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 377 | 0.430 |
Why?
|
| Health Status Indicators | 1 | 2014 | 118 | 0.420 |
Why?
|
| Social Environment | 1 | 2014 | 119 | 0.420 |
Why?
|
| Age Factors | 8 | 2022 | 2771 | 0.410 |
Why?
|
| United States | 20 | 2025 | 11200 | 0.400 |
Why?
|
| Ribonuclease III | 2 | 2025 | 101 | 0.390 |
Why?
|
| Language | 1 | 2014 | 203 | 0.390 |
Why?
|
| Prevalence | 9 | 2023 | 2578 | 0.390 |
Why?
|
| Glioma | 3 | 2024 | 478 | 0.380 |
Why?
|
| Noise | 2 | 2024 | 19 | 0.370 |
Why?
|
| Presbycusis | 3 | 2024 | 4 | 0.360 |
Why?
|
| Child | 20 | 2025 | 25061 | 0.330 |
Why?
|
| Carotid Artery Diseases | 2 | 2023 | 133 | 0.320 |
Why?
|
| Risk Factors | 15 | 2025 | 10393 | 0.290 |
Why?
|
| Social Isolation | 2 | 2025 | 43 | 0.280 |
Why?
|
| Disability Evaluation | 3 | 2020 | 188 | 0.280 |
Why?
|
| Child, Preschool | 12 | 2025 | 14330 | 0.260 |
Why?
|
| Walking | 2 | 2021 | 229 | 0.250 |
Why?
|
| Medicare | 4 | 2023 | 418 | 0.250 |
Why?
|
| Baltimore | 3 | 2024 | 18 | 0.240 |
Why?
|
| Neoplasm Grading | 2 | 2024 | 257 | 0.240 |
Why?
|
| Longitudinal Studies | 7 | 2024 | 1421 | 0.230 |
Why?
|
| Pinealoma | 1 | 2025 | 19 | 0.230 |
Why?
|
| Pineal Gland | 1 | 2025 | 21 | 0.230 |
Why?
|
| Odontoid Process | 1 | 2024 | 10 | 0.230 |
Why?
|
| Accelerometry | 2 | 2024 | 65 | 0.220 |
Why?
|
| Chordoma | 1 | 2024 | 18 | 0.220 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2025 | 63 | 0.220 |
Why?
|
| Pilot Projects | 3 | 2019 | 1384 | 0.220 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2025 | 160 | 0.220 |
Why?
|
| Astrocytoma | 1 | 2025 | 95 | 0.220 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 21 | 0.220 |
Why?
|
| Feasibility Studies | 3 | 2023 | 788 | 0.220 |
Why?
|
| Anxiety | 3 | 2022 | 962 | 0.220 |
Why?
|
| Nutrition Surveys | 3 | 2021 | 292 | 0.220 |
Why?
|
| Brain | 6 | 2024 | 3032 | 0.210 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2023 | 135 | 0.210 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 5050 | 0.210 |
Why?
|
| Cervical Vertebrae | 1 | 2024 | 105 | 0.210 |
Why?
|
| Wilms Tumor | 1 | 2025 | 116 | 0.210 |
Why?
|
| Proton Therapy | 1 | 2025 | 151 | 0.200 |
Why?
|
| Fatigue | 1 | 2024 | 194 | 0.200 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 35 | 0.200 |
Why?
|
| Infant | 8 | 2025 | 12762 | 0.200 |
Why?
|
| Precision Medicine | 2 | 2024 | 344 | 0.200 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2022 | 21 | 0.190 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2023 | 42 | 0.190 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2022 | 77 | 0.190 |
Why?
|
| Medical Oncology | 1 | 2024 | 229 | 0.190 |
Why?
|
| Deafness | 1 | 2023 | 82 | 0.190 |
Why?
|
| Hypertension | 2 | 2022 | 1288 | 0.190 |
Why?
|
| Patient Outcome Assessment | 1 | 2022 | 89 | 0.190 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2023 | 88 | 0.190 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 18 | 0.180 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 63 | 0.180 |
Why?
|
| Receptor, trkB | 1 | 2021 | 21 | 0.180 |
Why?
|
| Odds Ratio | 3 | 2020 | 1188 | 0.180 |
Why?
|
| Sensation Disorders | 1 | 2021 | 24 | 0.180 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2025 | 284 | 0.180 |
Why?
|
| White Matter | 2 | 2020 | 205 | 0.180 |
Why?
|
| Cigarette Smoking | 1 | 2022 | 62 | 0.170 |
Why?
|
| Frailty | 1 | 2023 | 131 | 0.170 |
Why?
|
| Neuropsychological Tests | 2 | 2023 | 952 | 0.170 |
Why?
|
| Cohort Studies | 6 | 2023 | 4920 | 0.170 |
Why?
|
| Waiting Lists | 1 | 2022 | 236 | 0.170 |
Why?
|
| Propensity Score | 2 | 2019 | 238 | 0.170 |
Why?
|
| Kidney Neoplasms | 1 | 2025 | 435 | 0.170 |
Why?
|
| Gadolinium | 1 | 2021 | 110 | 0.170 |
Why?
|
| Neoplasms | 3 | 2024 | 2848 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2025 | 3256 | 0.160 |
Why?
|
| Ganglioglioma | 1 | 2020 | 20 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2025 | 3680 | 0.160 |
Why?
|
| Early Diagnosis | 1 | 2021 | 179 | 0.160 |
Why?
|
| Corpus Callosum | 1 | 2020 | 103 | 0.160 |
Why?
|
| Self Report | 5 | 2025 | 535 | 0.160 |
Why?
|
| Supratentorial Neoplasms | 1 | 2020 | 36 | 0.160 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2020 | 16 | 0.160 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2020 | 21 | 0.160 |
Why?
|
| Mental Health | 3 | 2023 | 364 | 0.160 |
Why?
|
| Adolescent | 9 | 2025 | 19936 | 0.160 |
Why?
|
| Frail Elderly | 2 | 2023 | 104 | 0.160 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 19 | 0.160 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 28 | 0.160 |
Why?
|
| Interdisciplinary Research | 1 | 2019 | 9 | 0.160 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 148 | 0.160 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2019 | 20 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 1757 | 0.150 |
Why?
|
| Sex Factors | 3 | 2021 | 1294 | 0.150 |
Why?
|
| Genetic Counseling | 1 | 2021 | 235 | 0.150 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 415 | 0.150 |
Why?
|
| Radiation Dosage | 1 | 2019 | 126 | 0.150 |
Why?
|
| Communication Barriers | 1 | 2018 | 40 | 0.140 |
Why?
|
| Alzheimer Disease | 2 | 2023 | 835 | 0.140 |
Why?
|
| Patient Participation | 1 | 2021 | 230 | 0.140 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 780 | 0.140 |
Why?
|
| Hearing Loss, Unilateral | 1 | 2017 | 9 | 0.140 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 154 | 0.140 |
Why?
|
| Minority Health | 1 | 2017 | 13 | 0.140 |
Why?
|
| Aurora Kinase A | 1 | 2018 | 35 | 0.140 |
Why?
|
| Azepines | 1 | 2018 | 61 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 443 | 0.140 |
Why?
|
| Biomarkers, Tumor | 4 | 2023 | 1559 | 0.140 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2017 | 15 | 0.140 |
Why?
|
| Oximes | 1 | 2017 | 53 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 859 | 0.130 |
Why?
|
| Panniculitis | 1 | 2017 | 18 | 0.130 |
Why?
|
| Automobile Driving | 1 | 2017 | 31 | 0.130 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 620 | 0.130 |
Why?
|
| Neuroimaging | 1 | 2020 | 357 | 0.130 |
Why?
|
| Hormone Replacement Therapy | 1 | 2020 | 210 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2019 | 1175 | 0.130 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 118 | 0.130 |
Why?
|
| Health Status | 2 | 2017 | 379 | 0.130 |
Why?
|
| Adult | 8 | 2025 | 30253 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1095 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2017 | 142 | 0.130 |
Why?
|
| Young Adult | 5 | 2024 | 9617 | 0.130 |
Why?
|
| Prediabetic State | 1 | 2017 | 65 | 0.120 |
Why?
|
| Biomedical Research | 2 | 2019 | 527 | 0.120 |
Why?
|
| Happiness | 1 | 2016 | 12 | 0.120 |
Why?
|
| Imidazoles | 1 | 2017 | 217 | 0.120 |
Why?
|
| Germinoma | 1 | 2016 | 30 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 63 | 0.120 |
Why?
|
| Indoles | 1 | 2017 | 200 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 196 | 0.120 |
Why?
|
| Arousal | 1 | 2016 | 77 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 204 | 0.120 |
Why?
|
| Medulloblastoma | 1 | 2019 | 379 | 0.120 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 360 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2017 | 277 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 457 | 0.110 |
Why?
|
| Mass Screening | 1 | 2021 | 805 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1231 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3303 | 0.110 |
Why?
|
| Oncogene Fusion | 1 | 2014 | 24 | 0.110 |
Why?
|
| Cyclin B | 1 | 2014 | 22 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1763 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2025 | 16768 | 0.110 |
Why?
|
| Task Performance and Analysis | 1 | 2014 | 80 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1227 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2018 | 331 | 0.110 |
Why?
|
| Prognosis | 3 | 2025 | 4708 | 0.110 |
Why?
|
| Apolipoprotein E4 | 1 | 2014 | 47 | 0.110 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 142 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 163 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2015 | 599 | 0.100 |
Why?
|
| Environment | 1 | 2014 | 146 | 0.100 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 899 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 575 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 430 | 0.100 |
Why?
|
| Genomics | 2 | 2024 | 1570 | 0.100 |
Why?
|
| Mutation | 4 | 2023 | 5927 | 0.100 |
Why?
|
| Postural Balance | 1 | 2014 | 129 | 0.100 |
Why?
|
| Emotions | 1 | 2016 | 356 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2014 | 128 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2017 | 889 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 822 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2017 | 1087 | 0.100 |
Why?
|
| Speech | 2 | 2023 | 56 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 479 | 0.090 |
Why?
|
| Hearing Tests | 2 | 2023 | 16 | 0.090 |
Why?
|
| Incidence | 5 | 2019 | 3213 | 0.090 |
Why?
|
| Leisure Activities | 2 | 2023 | 9 | 0.090 |
Why?
|
| Sarcoma | 1 | 2014 | 205 | 0.090 |
Why?
|
| Disease Management | 1 | 2016 | 533 | 0.090 |
Why?
|
| Diet | 1 | 2019 | 1102 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2016 | 1187 | 0.090 |
Why?
|
| Germ Cells | 2 | 2024 | 196 | 0.090 |
Why?
|
| DNA Mismatch Repair | 2 | 2022 | 50 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 588 | 0.090 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2023 | 79 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 3905 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2014 | 762 | 0.080 |
Why?
|
| Time Factors | 2 | 2019 | 6007 | 0.080 |
Why?
|
| Alleles | 1 | 2014 | 1611 | 0.080 |
Why?
|
| Software | 1 | 2014 | 710 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 1350 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2021 | 8357 | 0.070 |
Why?
|
| Obesity | 1 | 2019 | 2330 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1353 | 0.060 |
Why?
|
| Hospitalization | 1 | 2015 | 1838 | 0.060 |
Why?
|
| Audiometry | 2 | 2017 | 22 | 0.060 |
Why?
|
| Blood Pressure | 2 | 2022 | 1305 | 0.060 |
Why?
|
| Heart Failure | 1 | 2018 | 2173 | 0.060 |
Why?
|
| Tennessee | 2 | 2014 | 34 | 0.060 |
Why?
|
| Equivalence Trials as Topic | 1 | 2024 | 21 | 0.050 |
Why?
|
| Hand Strength | 1 | 2024 | 56 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2024 | 79 | 0.050 |
Why?
|
| Social Networking | 1 | 2024 | 16 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 1596 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2022 | 1888 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 39 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2022 | 52 | 0.050 |
Why?
|
| Polysomnography | 1 | 2023 | 147 | 0.050 |
Why?
|
| Carotid Arteries | 1 | 2023 | 130 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2023 | 225 | 0.050 |
Why?
|
| Multiple Chronic Conditions | 1 | 2021 | 13 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2021 | 48 | 0.040 |
Why?
|
| Life Change Events | 1 | 2022 | 63 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 291 | 0.040 |
Why?
|
| Maryland | 1 | 2021 | 35 | 0.040 |
Why?
|
| Mississippi | 1 | 2021 | 34 | 0.040 |
Why?
|
| North Carolina | 1 | 2021 | 61 | 0.040 |
Why?
|
| Minnesota | 1 | 2021 | 172 | 0.040 |
Why?
|
| Social Class | 1 | 2022 | 198 | 0.040 |
Why?
|
| Bias | 1 | 2021 | 134 | 0.040 |
Why?
|
| Sleep | 1 | 2023 | 352 | 0.040 |
Why?
|
| Motor Activity | 1 | 2023 | 504 | 0.040 |
Why?
|
| Auditory Threshold | 1 | 2019 | 15 | 0.040 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2019 | 22 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 757 | 0.040 |
Why?
|
| China | 1 | 2020 | 274 | 0.040 |
Why?
|
| Ethics Committees, Research | 1 | 2019 | 27 | 0.040 |
Why?
|
| Exome | 1 | 2024 | 1064 | 0.040 |
Why?
|
| Ophthalmic Artery | 1 | 2019 | 17 | 0.040 |
Why?
|
| Biomarkers | 2 | 2019 | 3138 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1174 | 0.040 |
Why?
|
| Ethics, Research | 1 | 2019 | 54 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 140 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 101 | 0.040 |
Why?
|
| Carotid Artery, Internal | 1 | 2019 | 56 | 0.040 |
Why?
|
| Longitudinal Ligaments | 1 | 2019 | 3 | 0.040 |
Why?
|
| Mental Competency | 1 | 2019 | 54 | 0.040 |
Why?
|
| Carotid Artery, Common | 1 | 2019 | 59 | 0.040 |
Why?
|
| Research Subjects | 1 | 2019 | 50 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2019 | 92 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 391 | 0.040 |
Why?
|
| Disease Progression | 1 | 2025 | 2099 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2019 | 42 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 866 | 0.040 |
Why?
|
| Delirium | 1 | 2019 | 65 | 0.040 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2020 | 243 | 0.040 |
Why?
|
| Phenotype | 2 | 2019 | 4304 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2025 | 871 | 0.040 |
Why?
|
| Contrast Media | 1 | 2021 | 459 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 909 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2018 | 139 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2017 | 51 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 332 | 0.030 |
Why?
|
| Research Design | 1 | 2021 | 687 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 397 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 2019 | 315 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 695 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3532 | 0.030 |
Why?
|
| Internal-External Control | 1 | 2016 | 74 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 758 | 0.030 |
Why?
|
| Focus Groups | 1 | 2016 | 215 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 189 | 0.030 |
Why?
|
| Self Concept | 1 | 2016 | 155 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2018 | 388 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 930 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2015 | 255 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 934 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 567 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2014 | 57 | 0.030 |
Why?
|
| Minority Groups | 1 | 2016 | 250 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1537 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 726 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 380 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 686 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 331 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2016 | 429 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 529 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2019 | 1060 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2024 | 2967 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2016 | 658 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1476 | 0.020 |
Why?
|
| Patient Selection | 1 | 2016 | 702 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 3460 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 1744 | 0.020 |
Why?
|
| Apoptosis | 1 | 2018 | 1805 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 3484 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2180 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2014 | 542 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1733 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 12315 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 4406 | 0.020 |
Why?
|
| Animals | 2 | 2018 | 33105 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 2022 | 0.010 |
Why?
|